Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

NCT02682641 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: IBRUTINIB
DRUG: Rituximab

Sponsor

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Collaborators

[object Object]